Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 7/20 | 0.48 |
| ▸ | ACACA | Q13085 | 7/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345345 | 0.86 | HRH3 (0.50) | PDE10APDE2AHRH3CHRM4 | |
| SCHEMBL22499904 | 0.80 | PDE10A (0.58) | SUV39H2PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL29689781 | 0.80 | PDE10A (0.58) | SUV39H2PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL2405732 | 0.80 | PDE10A (0.40) | ACACBACACAPDE10APDE2AHRH3 | |
| SCHEMBL345088 | 0.80 | PDE10A (0.44) | ACACBACACAPDE10APDE2AHRH3 | |
| SCHEMBL345436 | 0.79 | PDE10A (0.40) | SIRT2SIRT1SIRT3ACACBACACA | |
| SCHEMBL1722961 | 0.79 | PDE10A (0.48) | PDE10APDE2AHRH3CHRM4 | |
| SCHEMBL345206 | 0.76 | PDE10A (0.53) | PDE10APDE2AHRH3 | |
| SCHEMBL1729968 | 0.75 | HRH3 (0.58) | ACACBHRH3CHRM4 | |
| SCHEMBL346471 | 0.75 | CHRM4 (0.52) | SUV39H2SIRT2SIRT1SIRT3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | SUV39H2 2182/4885SIRT2 543/4885SIRT1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.